Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
Top Cited Papers
Open Access
- 18 November 2020
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 10 (11), 1575
- https://doi.org/10.3390/biom10111575
Abstract
The potential therapeutic use of some Cannabis sativa plant compounds has been attracting great interest, especially for managing neuropsychiatric disorders due to the relative lack of efficacy of the current treatments. Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displays an interesting pharmacological profile without the potential for becoming a drug of abuse, unlike THC. In this review, we focused on the anxiolytic, antidepressant, and antipsychotic effects of CBD found in animal and human studies. In rodents, results suggest that the effects of CBD depend on the dose, the strain, the administration time course (acute vs. chronic), and the route of administration. In addition, certain key targets have been related with these CBD pharmacological actions, including cannabinoid receptors (CB1r and CB2r), 5-HT1A receptor and neurogenesis factors. Preliminary clinical trials also support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and more importantly, a positive risk-benefit profile. These promising results support the development of large-scale studies to further evaluate CBD as a potential new drug for the treatment of these psychiatric disorders.This publication has 209 references indexed in Scilit:
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI StudyNeuropsychopharmacology, 2011
- Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia PatientsNeuropsychopharmacology, 2011
- The GABAergic deficit hypothesis of major depressive disorderMolecular Psychiatry, 2010
- Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.Pharmacology Biochemistry and Behavior, 2010
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and PsychopathologyNeuropsychopharmacology, 2009
- Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Δ9-tetrahydrocannabinolDrug and Alcohol Dependence, 2008
- The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitroBritish Journal of Pharmacology, 2007
- Chronic mild stress-induced anhedonia: A realistic animal model of depressionNeuroscience & Biobehavioral Reviews, 1992